Page last updated: 2024-12-05

isoxsuprine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isoxsuprine is a sympathomimetic drug that acts as a vasodilator. It is used to treat peripheral vascular disease, especially in cases of intermittent claudication. Isoxsuprine is thought to work by relaxing smooth muscle in the blood vessels, which increases blood flow. The compound is typically administered orally, but can also be given intravenously. Isoxsuprine is available in various countries. In the United States, it is only available through compounding pharmacies. Isoxsuprine is an effective treatment for peripheral vascular disease and is generally well-tolerated. However, it can cause side effects, such as headache, dizziness, and nausea. The molecule is derived from the adrenergic agonist epinephrine and was first synthesized in the 1950s. It has been studied for its potential to treat other conditions, such as Raynaud's phenomenon and erectile dysfunction. However, more research is needed to fully understand its efficacy and safety in these conditions. It is still a topic of interest for researchers due to its unique mechanism of action and potential to treat a variety of conditions.'

Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3783
CHEMBL ID1197051
CHEBI ID91855
SCHEMBL ID181079
MeSH IDM0011809

Synonyms (36)

Synonym
BRD-A74269027-003-03-8
benzenemethanol, 4-hydroxy-.alpha.-[1-[(1-methyl-2-phenoxyethyl)amino]ethyl]-
benzyl alcohol, p-hydroxy-.alpha.-(1-((1-methyl-2-phenoxyethyl)amino)ethyl)-
4-(1-hydroxy-2-{[1-methyl-2-(phenyloxy)ethyl]amino}propyl)phenol
395-28-8
benzenemethanol, 4-hydroxy-.alpha.-[1-[(1-methyl-2-phenoxyethyl)amino]ethyl]-, hydrochloride
isoxsuprine
4-[1-hydroxy-2-[(1-methyl-2-phenoxy-ethyl)amino]propyl]phenol
BSPBIO_000255
PRESTWICK3_000068
PRESTWICK2_000068
BPBIO1_000281
PRESTWICK1_000068
PRESTWICK0_000068
SPBIO_002176
D08092
isoxsuprine (inn)
dilator (tn)
4-[1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol
CHEMBL1197051
NCGC00018295-02
SCHEMBL181079
isoxuprine
p-hydroxy-.alpha.-(1-((1-methyl-2-phenoxyethyl)amino)ethyl)benzyl alcohol
BMUKKTUHUDJSNZ-UHFFFAOYSA-N
4-(1-hydroxy-2-[(1-methyl-2-phenoxyethyl)amino]propyl)phenol #
duvadilan (salt/mix)
4-hydroxy-.alpha.-[1-[(1-methyl-2-phenoxyethyl)amino]ethyl]benzyl alcohol
erythro-1-(p-hydroxyphenyl)-2-(.alpha.-methyl-.beta.-phenoxyethylamino)propanol
1-(p-hydroxyphenyl)-2-(1'-methyl-2'-phenoxyethylamino)propanol-2-hydrochloride (salt/mix)
vasodilan (salt/mix)
CHEBI:91855
Q1117888
1-(p-hydroxyphenyl)-1-propanol
4-{1-hydroxy-2-[(1-phenoxypropan-2-yl)amino]propyl}phenol
EN300-18552793

Research Excerpts

Overview

Isoxsuprine is a beta-agonist that can be used for growth promotion in cattle, but it is also used as registered veterinary medicine. It is a therapeutic medication used to treat navicular disease and other lower limb problems in horses and is one of the more frequently detected therapeutic agents in racing horses.

ExcerptReferenceRelevance
"Isoxsuprine was found to be an effective and well-tolerated tocolytic agent in arresting PTL, in turn resulting in the overall improvement in maternal and perinatal outcomes."( Effectiveness and Safety of Isoxsuprine Hydrochloride as Tocolytic Agent in Arresting Active/Threatened Preterm Labor and Its Role in Maintenance Tocolysis: A Prospective, Open-Label Study.
Jaju, PB, 2021
)
2.36
"Isoxsuprine is a beta-agonist that can be used for growth promotion in cattle, but it is also used as registered veterinary medicine. "( Veterinary treatment of cows with isoxsuprine for a caesarian section may temporarily lead to residues in hair of both cow and calf.
Groot, MJ; Lasaroms, JJ; Nielen, MW; Van Hende, J, 2012
)
2.1
"Isoxsuprine is a therapeutic medication used to treat navicular disease and other lower limb problems in horses and is one of the more frequently detected therapeutic agents in racing horses. "( Character and duration of pharmacological effects of intravenous isoxsuprine.
Harkins, JD; Mundy, GD; Richardson, DR; Sams, RA; Stanley, S; Tobin, T; Woods, WE, 1996
)
1.97
"Isoxsuprine is an alpha 1-selective adrenoceptor antagonist but has very low potency and efficacy as a beta-adrenoceptor agonist in this functional bioassay."( Characterisation of beta-adrenoceptors in equine digital veins: implications of the modes of vasodilatory action of isoxsuprine.
Elliott, J; Soydan, J, 1995
)
1.22
"Isoxsuprine is an affective, quick and economical hypotensive of easy management that has no adverse effects on mother-fetus glycemia, obstetric bleeding and APGAR score."( [Isoxsuprine in hypertension during pregnancy].
Briones-Garduño, JC; González-Alvarez, R,
)
1.76
"Isoxsuprine is reported to be a peripheral vasodilator used in human and veterinary medicine to treat ischaemic vascular disease. "( Absence of detectable pharmacological effects after oral administration of isoxsuprine.
Grambow, SC; Harkins, JD; Mundy, GD; Richardson, DR; Sams, RA; Stanley, S; Tobin, T; Woods, WE, 1998
)
1.97
"Isoxsuprine is a potent vasodilator of arterial smooth muscle that has been precontracted by an alpha-adrenoceptor agonist such as noradrenaline (log EC50 = -6.33 [-5.98; -6.68])."( Affinity of isoxsuprine for adrenoreceptors in equine digital artery and implications for vasodilatory action.
Arioli, F; Belloli, C; Beretta, C; Carcano, R, 2000
)
1.41

Effects

ExcerptReferenceRelevance
"Isoxsuprine has an apparent affinity for melanin that may contribute to extended renal excretion."( Isoxsuprine hydrochloride in the horse: a review.
Erkert, RS; Macallister, CG, 2002
)
2.48
"Isoxsuprine hydrochloride has been suggested for use in horses for treatment of navicular syndrome and laminitis. "( Isoxsuprine hydrochloride in the horse: a review.
Erkert, RS; Macallister, CG, 2002
)
3.2

Actions

Isoxsuprine failed to increase blood flow in the calf, foot or hand. It did not alter blood pressure or heart rate significantly.

ExcerptReferenceRelevance
"Isoxsuprine appeared to inhibit the saline-induced increase."( Characterization and comparison of the role of beta-agonists on in vivo and in vitro surfactant-related phospholipid synthesis and secretion by fetal rabbit lung and isolated type II alveolar cells.
Oulton, MR; Rasmusson, MG; Scott, JE; Temple, S, 1988
)
1
"Isoxsuprine failed to increase blood flow in the calf, foot or hand, and did not alter blood pressure or heart rate significantly."( Isoxsuprine as an oral vasodilator.
Baird, RJ; Zsotér, TT, 1974
)
2.42

Treatment

ExcerptReferenceRelevance
"Isoxsuprine treatment appeared to have no specific effect on the levels of either estradiol alone or on total estrogens with all patients studied showing some increase in the concentrations of these estrogens as the pregnancies approached term."( The effect of isoxsuprine treatment of estrogen levels in maternal and umbilical cord plasma.
Maughan, GB; Sybulski, S, 1975
)
1.34

Toxicity

ExcerptReferenceRelevance
" Thus, in utero treatment with isoxsuprine had no apparent adverse effect on newborn rats exposed to a prolonged O2 challenge."( Effect of prenatal isoxsuprine on pulmonary oxygen toxicity in the newborn rat.
Frank, L; Massaro, D; Summerville, J, 1980
)
0.88

Bioavailability

ExcerptReferenceRelevance
" Thus, YC-93 is a potent bu low-toxic vasodilator agent acting preferentially and perhaps directly on cerebral and coronary vascular beds and is well absorbed from gastrointestinal tract into blood stream."( Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93).
Maeno, H; Nomura, T; Sado, T; Takenaka, T; Usuda, S, 1976
)
0.26

Dosage Studied

Plasma total isoxsuprine, determined in three horses, was detectable two hours after oral dosing and maximal eight hours after dosing. A new, simple, sensitive and rapid spectrofluorimetric method has been developed for determination of adrenergic agonists.

ExcerptRelevanceReference
"The authors report two cases of severe non-obstructive cardiomyopathy presenting at the end of pregnancy in young women treated for long periods and at high dosage with beta 2-adrenoceptor stimulants, prescribed for threatened abortion or premature labour."( [Myocardiopathies during pregnancy. Possible role of beta-mimetics].
Bourdonnec, C; Daubert, JC; Gosse, P; Gouffault, J; Grall, JY; Pony, JC; Rio, M, 1978
)
0.26
"A reliable and selective high-pressure liquid chromatographic (HPLC) procedure for the quantitative determination of nylidrin hydrochloride or isoxsuprine hydrochloride in pharmaceutical dosage forms is described."( High-performance liquid chromatography of two peripheral vasodilators, nylidrin hydrochloride and isoxsuprine hydrochloride, in pharmaceutical dosage forms.
Spiegel, D; Volpe, F; Zintel, J, 1979
)
0.68
" Plasma total isoxsuprine, determined in three horses, was detectable two hours after oral dosing and maximal eight hours after dosing, but free isoxsuprine could not be detected."( Effect of an isoxsuprine-resin preparation on blood flow in the equine thoracic limb.
de Haan, F; Deumer, J; Tulp, MT; van den Hoven, R, 1991
)
1.01
" Duration of exposure to tocolysis was at least 30 days (30-180 days) with an oral dosage of 10 mg 3 times daily."( Transient electrocardiographic changes suggesting myocardial ischaemia in newborn infants following tocolysis with beta-sympathomimetics.
Agnetti, A; De Luca, F; Di Pasquale, G; Gemelli, M; Leonardi, R; Mami, C; Manganaro, R; Rando, F, 1990
)
0.28
" When a recommended therapeutic dosage regimen (0."( Cardiovascular and pharmacokinetic effects of isoxsuprine in the horse.
Burrows, K; Gleed, RD; Matthews, NS; Short, CE, 1986
)
0.53
" Preincubation with cocaine, 10(-5) M, shifted the inhibitory dose-response curves of Iso and Orc to the left, 16."( Mechanism of action of isoprenaline, isoxuprine, terbutaline and orciprenaline on gravid human isolated myometrium. Influence of the neuronal uptake process.
Calixto, JB; Simas, CM, 1984
)
0.27
" We guess that SP can be used in well regulated dosed with least side effects to arrest preterm labor on human being in the future."( The effect of spironolactone on the rat uterus.
Coksevim, B; Tayyar, M, 1994
)
0.29
" To define the scope and duration of its pharmacological responses after oral administration, 6 horses were dosed with isoxsuprine HCl (1."( Absence of detectable pharmacological effects after oral administration of isoxsuprine.
Grambow, SC; Harkins, JD; Mundy, GD; Richardson, DR; Sams, RA; Stanley, S; Tobin, T; Woods, WE, 1998
)
0.74
"A simple and highly sensitive voltammetric method was developed for the determination of isoxsuprine HCl (I) and fenoterol HBr (II) in dosage forms and biological fluids."( Voltammetric determination of isoxsuprine and fenoterol in dosage forms and biological fluids through nitrosation.
Al-Majed, AA; Al-Malaq, HA; Belal, F, 2000
)
0.82
" The method was applied successfully in determining the drugs in dosage forms and in biological fluids."( Determination of phenolic sympathomimetic drugs in pharmaceutical samples and biological fluids by flow-injection chemiluminescence.
Al-Tamimi, SA; Alwarthan, AA; Aly, FA,
)
0.13
"A simple, accurate, and rapid method for the quantitative determination of ritodrine hydrochloride (RTH) and isoxsuprine hydrochloride (ISH) in both pure and dosage forms, is described."( Spectrophotometric determination of ritodrine and isoxsuprine hydrochlorides using 4-aminoantipyrine.
Manju, BG; Revanasiddappa, HD,
)
0.6
"Two simple and highly sensitive fluorimetric methods have been developed for the determination of isoxsuprine hydrochloride in bulk, in dosage forms and in biological fluids."( Fluorimetric determination of isoxsuprine hydrochloride in pharmaceuticals and biological fluids.
Alarfaj, NA, 2002
)
0.82
"A new, simple, sensitive and rapid spectrofluorimetric method has been developed for determination of certain adrenergic agonists such as isoxsuprine hydrochloride, ritodrine hydrochloride and etilefrine hydrochloride in their pure forms and pharmaceutical dosage forms."( Spectrofluorimetric determination of certain adrenergic agonist drugs in their pure forms and pharmaceutical formulations: Content uniformity test application.
Attia, TZ; Badr El-Din, KM, 2017
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
alkylbenzeneA monocyclic arene that is benzene substituted with one or more alkyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)572.50000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (23)

Assay IDTitleYearJournalArticle
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1136412Displacement of (-)-[3H]alprenolol from adrenergic receptor purified from frog erythrocytes1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Structure-activity study of beta-adrenergic agents using the SIMCA method of pattern recognition.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (391)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990306 (78.26)18.7374
1990's26 (6.65)18.2507
2000's19 (4.86)29.6817
2010's37 (9.46)24.3611
2020's3 (0.77)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 76.59

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index76.59 (24.57)
Research Supply Index6.13 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index134.98 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (76.59)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials33 (7.78%)5.53%
Reviews22 (5.19%)6.00%
Case Studies23 (5.42%)4.05%
Observational0 (0.00%)0.25%
Other346 (81.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse [NCT03752307]Phase 1/Phase 22 participants (Actual)Interventional2019-02-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]